目的:观察去甲氧柔红霉素(IDA)与柔红霉素(DNR)、米托蒽醌(MTN)、吡柔比星(THP)治疗急性髓系白血病的疗效和毒副反应。方法:选择我院2005年4月~2010年4月住院的62例急性髓系白血病患者,随机分为2组,治疗组30例采用IDA+阿糖胞苷(Ara-C)治疗,对照组32例采用DNR(或MTN、THP)+Ara-C治疗。结果:治疗组和对照组完全缓解率(CR)分别为80.0%和43.8%,总有效率(RR)分别为93.3%和68.8%,临床严重感染率分别为36.7%和34.4%。2组CR和RR比较,差异有统计学意义(P〈0.05),但2组的严重感染率比较,差异无统计学意义(P〉0.05)。结论:以IDA组成的联合化疗方案治疗急性髓系白血病疗效较好。
OBJECTIVE: To investigate clinical efficacy and toxic reaction of idarubicin (IDA), daunorubicin (DNR), mitoxantrone (MTN) and theprubicine (THP) in the treatment of acute myeloid leukemia. METHODS: 62 patients with acute myeloid leukemia were selected from our hospital during the period of Apr. 2005~Apr. 2010 and randomly divided into 2 groups. Treatment group received IDA and Ara-C (n=30) and control group DNR, MTN or THP combined with Ara-C (n=32). RESULTS: The complete remission (CR) rates were 80.0% for treatment group and 43.8% for control group. The total effective rates (RR) of treatment group and control group were 93.3% and 68.8%, respectively. The rates of severe infection in the clinic were 36.7% and 34.4%, respectively. There were statistical significances in the difference of CR rate and RR rate between 2 groups (P〈0.05), while there was no statistical significance in the differences of rate of severe infection between 2 groups (P〉0.05). CONCLUSION: Combined chemotherapeutic scheme containing IDA have sound effect on the acute myeloid leukemia.